(Reuters) – Gilead Sciences Inc’s experimental drug remdesivir, seen as one of the more promising potential treatments for the coronavirus, on Monday received the orphan drug designation from the U.S. Food and Drug Administration. The announcement comes days a... More »
(Reuters) – Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer. A jury in Los Angeles awarded the damages after finding that Yescarta, a trea... More »
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. Out of 101 patients teated with Yescarta for ... More »
(Reuters) – Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG’s Daniel O’Day as its new chief executive, tapping an industry veteran to fill a management vacuum. O’Day, now head of Roche’s pharmaceuticals business, joined the company in 1987 and h... More »
The logo of Gilead Sciences Inc is pictured during a news conference in New Delhi September 15, 2014. REUTERS/Anindito Mukherjee/File Photo (Reuters) – A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2... More »
Shares of Gilead Sciences Inc are languishing over concerns about the U.S. biotechnology company’s declining hepatitis C drugs and profit outlook, but some value investors sense an opportunity with shares at extremely cheap levels. More »
SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages award is far less than the $2... More »
